Loading...

GLENMARK Glenmark Pharmaceuticals Ltd Legal Disputes Announcement

Glnm

GLNM

Glenmark Pharmaceuticals Ltd

(GLENMARK)

2026 Announcement

Litigation settlement

New Development Candidate

Results Approval

New Product Launch

Large Corporate status

Regulatory disclosure

New Product Launch

GST tax dispute

Geographic Expansion

New Product Launch

Authorized Generic Launch

New Product Launch

New Product Launch

New Product Launch

ESG rating disclosure

Special Window Transfer

Earnings Call Transcript

Analyst / Institutional Inv...

Board approval of results

Earnings Call Invitation

Trading window closure

Board Meeting Intimation

ESG Rating Disclosure

New Product Launch

Exclusive license agreement

New Product Launch

Pre-Approval Inspection

FDA inspection outcome

New Product Launch

Earnings Call Transcript

Market authorization and EU...

Analyst / Investor Meet

Investor Presentation

Earnings results

Unaudited results

Litigation Settlement

China Approval Granted

Earnings Call Announcement

New Product Launch

Trading Window Closure

Board Meeting Announcement

Oncology Partnership

Credit Rating Update

Consumer Care Transfer

$700M Upfront Payment

Investor Meetings

AGM Announcement

Share Transfer Update

Earnings Call Transcript

Investor Meetings

Book Closure Notice

Investment Update

New Product Launch

Investor Meeting

Investor Presentation

Business Transfer

Secretarial Auditor Appoint...

Auditor Appointment

Director Appointment

Q1 FY26 Results

Earnings Call Scheduled

Legal Settlement

IEPF Share Transfer

Credit Rating Update

Investor Day 2025

Investor Presentation

FDA Warning Letter

Investor Meeting Notice

Commercialization Strategy

Licensing Agreement

Postal Ballot Notice

Key Personnel Announcement

TEVIMBRA Launch

Director Cessation

FDA Inspection Outcome

BRUKINSA Launch

Promising Study Results

Earnings Call Transcript

Annual Compliance Report

Earnings Call Recording

New Subsidiary Launch

Investor Presentation

Q4 FY25 Results

Management Change

Stock Options Granted

Earnings Call Notice

FDA Inspection Update

FDA Fast Track Designation

New Product Launch

Management Change

Facility Closure

Postal Ballot Notice

FDA Approval Received

New Diabetes Drug

New Product Launch

Investor Meeting Scheduled

Epinephrine Launch

Legal Settlement

Earnings Call Transcript

Investor Meeting

Q3 Earnings Call

FDA Inspection Results

Directorate Changes

Investor Presentation

Q3 Earnings Report

New Product Launch

New Product Launch

Winlevi Approval

GST Demand Notice

GST Demand Order

Earnings Call Scheduled

Glenmark Acquisition

Positive Clinical Data

Earnings Call Transcript

Earnings Call Update

Investor Presentation

Q2 FY 2024-25 Results

Earnings Call Scheduled

FDA Inspection Result

FDA Inspection Results

Investor Meetings

AGM Notice Issued

Settlement Agreement

Earnings Call Transcript

New Product Launch

Earnings Call Update

Investor Presentation

Q1 Performance Update

Transfer of Equity Shares t...

Sale of Equity Shares

Audio Recording

Investor Presentation

Earnings Call Transcript

Compliance Report Submission

Earnings Call Outcome

Investor Presentation

Financial Results

Cost Auditor Appointment

Partnership Agreement for C...

Investor Day 2024

Credit Rating Upgrade

Certificate Submission

Compliance Certification

Credit Rating Update

Credit Rating Upgrade

Equity Shares Transfer

Equity Shares Transfer

Disposal of Assets

Meeting Schedule

Earnings Call Transcript

Investor Presentation

Financial Results

Allotment of ESOP

Partnership for Abrocitinib...

alliance for innovation in ...

License Agreement

Earnings Call Transcript

Analyst Meetings

Investor Presentation

Financial Results Announcement

Launch of Triple-Drug FDC f...

Licensing Agreement

Advertisement Publication

Credit Rating Update

Distribution and License Ag...

Changes in credit ratings

Meeting Schedule

Promotion of Senior Manager...

AGM Advertisement

Financial Statements

New Product Launches

Upload of Earnings Call

Financial Statements

Merger of Equals

Newspaper Advertisement

Debt Restructuring

Debt Restructuring

Earnings Call Transcript

Related Party Transaction D...

Management Changes

Investor Presentation

Financial Statements

Wholly-owned Subsidiary

External Links:

Data:

Glenmark reaches a $29.628 million antitrust settlement with U.S. state attorneys general, payable over five years, subject to court approval; no admission of liability and no material impact on finances.

AI Assistant

Glenmark Pharmaceuticals Ltd

2026

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.